Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Brokerages

Vor Biopharma Inc. (NYSE:VOR) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.92.

Several analysts recently issued reports on VOR shares. Oppenheimer restated an “outperform” rating and issued a $10.00 price target (down from $15.00) on shares of Vor Biopharma in a research note on Monday, May 13th. Barclays reduced their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Friday, May 10th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Monday, May 13th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VOR. Acadian Asset Management LLC raised its position in shares of Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after buying an additional 27,597 shares in the last quarter. Hsbc Holdings PLC increased its stake in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after acquiring an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vor Biopharma during the second quarter valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vor Biopharma during the second quarter worth $63,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of VOR opened at $0.99 on Wednesday. The firm has a market capitalization of $67.72 million, a PE ratio of -0.56 and a beta of -0.34. The company’s 50-day moving average is $0.99 and its 200-day moving average is $1.57. Vor Biopharma has a fifty-two week low of $0.70 and a fifty-two week high of $3.14.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). Analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.